Company Focus
CVS Health
Latest CVS Health News
Pharmaceutical
Following the news that Donald Trump is the winner of the 2024 US Presidential Election, Morningstar Equity analyst Julie Utterback has published a new note about the impact of this on the managed-care industry. 7 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing atacicept and other targeted therapies for serious immunological and kidney diseases with high unmet medical need.
Latest News & Features of interest to CVS Health
Biotechnology
The US Food and Drug Administration (FDA) has approved pharma giant Pfizer and Japanese drugmaker Astellas Pharma’s Padcev (enfortumab vedotin-ejfv) plus Merck & Co’s Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adults with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility. 10 July 2026
Biotechnology
The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all existing indications of Sarclisa intravenous (IV) formulation. 10 July 2026
Biotechnology
Chinese drugmaker Hansoh Pharma says its GSK-partnered antibody-drug conjugate risvutatug rezetecan, or Ris-Rez, has met the primary endpoint of overall survival in a pivotal Phase III trial in small cell lung cancer. 10 July 2026
Pharmaceutical
Sweden-based KDventures AB today announced that its portfolio company PharmNovo has completed a capital raise of approximately 39 million kronor ($4.1 million), with participation from external investors. 10 July 2026
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance rejecting routine National Health Service (NHS) use of Amgen’s Lumykras (sotorasib) for previously treated KRAS G12C-mutated advanced non-small-cell lung cancer. 10 July 2026
Generics
Hyderabad, India-based Natco Pharma shares gained nearly 3% after unveiling a $300 million investment plan in South Africa aimed at strengthening its footprint across new geographies. 10 July 2026
Pharmaceutical
Roche has discontinued two Huntington’s disease programmes, ending the long-running development of tominersen after a Phase II efficacy failure and stopping an early-stage study of RG6496 because animal findings indicated that the experimental therapy could not be administered repeatedly. 10 July 2026
Biotechnology
Amprion and Modality.AI have formed a collaboration to explore the combined use of molecular biomarkers and artificial intelligence-enabled digital assessments in neurodegenerative disease research. The companies aim to connect evidence of underlying disease biology with measurable changes in speech, cognition, facial expression and behaviour. 10 July 2026
Biotechnology
GSK has terminated its neurodegeneration collaboration with Alector, ending an alliance established five years ago around two experimental antibodies. The decision follows clinical setbacks in frontotemporal dementia and early Alzheimer’s disease, which left neither of the partnered programmes in active development. 10 July 2026
Generics
India's Dr Reddy's Laboratories today revealed that supplies of its generic semaglutide would remain unavailable in India and face disruptions in Canada until at least late October after an issue with the active pharmaceutical ingredient (API) halted new production. 9 July 2026
Latest In Brief for CVS Health
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze